Leo Pharma recently announced that it signed an agreement to acquire U.S.-listed Timber Pharmaceuticals. And upon closing, this deal will add an attractive late-stage asset to LEO Pharma’s pipeline in medical dermatology. The deal is subject to certain closing conditions, including, but not limited to, Timber Pharmaceuticals’ shareholder approval.
The deal represents a total transaction value of up to $36 million with (i) an initial upfront consideration of $14 million and (ii) up to an additional $22 million in contingent value rights (CVRs) payable upon achievement of certain milestones.
Timber Pharmaceuticals’ lead investigational product candidate TMB-001 is a topical reformulation of the active ingredient, isotretinoin, which is aimed at treating congenital ichthyosis – a rare skin disease with significant unmet need and no approved prescription therapies available.
Isotretinoin is an API that today only exists in an oral formulation in the U.S. The reformulation TMB-001 has received an orphan and breakthrough designation by the FDA and is on track with an action date as early as mid-2025. TMB-001 has shown positive results in Phase 2, with Phase 3 recruitment currently ongoing in the US and in Europe.
The deal is pending final Timber Pharmaceuticals’ shareholder approval and certain other closing conditions before the transaction can be closed – expected to happen in the fourth quarter of 2023.
KEY QUOTES:
“Signing an agreement to acquire Timber Pharmaceuticals and TMB-001, which is still subject to certain closing conditions, is an additional step in delivering on our strategy. We will add an attractive late-stage asset to our medical dermatology pipeline and strengthen our team in the US. And most importantly, we will add an asset with promising outlook to be able to help patients suffering from a debilitating disease that today have no proper treatment options.”
— Christophe Bourdon, CEO of LEO Pharma
“We are very pleased to deliver a transaction that will maximize long term value for Timber Pharmaceuticals’ shareholders. LEO Pharma is a leader in global dermatology with a mission that matches our own – a relentless pursuit to help patients suffering from skin diseases. LEO’s expertise and global footprint make it the best choice to advance and achieve the full potential of Timber Pharmaceuticals’ portfolio of product candidates. We believe that LEO has the potential to establish TMB-001 as the standard of care in the treatment of congenital ichthyosis, a devastating, rare disease.”
— John Koconis, Chairman and Chief Executive Officer of Timber Pharmaceuticals
